Drug Co. Investors Seek OK For Early $3.8M Settlement
A putative class of investors in Amicus Therapeutics Inc. who said the company's misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a...To view the full article, register now.
Already a subscriber? Click here to view full article